Nasyrova, Regina F.,
Khasanova, Aiperi K.,
Altynbekov, Kuanysh S.,
Asadullin, Azat R.,
Markina, Ekaterina A.,
Gayduk, Arseny J.,
Shipulin, German A.,
Petrova, Marina M.,
Shnayder, Natalia A. (2022) the search for new therapeutic strategies for a
disease-modifying therapy for treatment-resistant Sch (TRS
. The average incidence of NF1 in the world is 1:3000 of the population. The characteristic signs of the
diseaseBeilerli, A.,
Kudriashov, V.,
Sufianov, A.,
Kostin, A.,
Begliarzade, S.,
Ilyasova, T.,
Liang, Ya.,
Mukhamedzyanov, A.,
Beylerli, O. (2023) RNAs) as dynamic
modifiers in the pathogenesis of various
diseases. MiRNAs are a separate class of RNA molecules
Importance of Novel Intraperitoneal Therapy of NF-kappa B Inhibitor DHMEQImportance of Novel Intraperitoneal
Therapy of NF-kappa B Inhibitor DHMEQ
with microdeletions are characterized by more severe
disease symptoms (more often facial dysmorphism, skeletal
and their long-term effects are caused by
modified expression of retroelements in neurons due to viral effect